Selling Your Veterinary Practice to Rarebreed Veterinary Partners: A Vet’s 2026 Guide

Key takeaways

• Rarebreed Veterinary Partners is a private equity-backed veterinary support-services platform founded in 2018 and headquartered in Portland, Maine. It remains operator-led under co-founder and CEO Dan Espinal.
• Revelstoke Capital Partners is the majority sponsor following a December 2021 recapitalization investment, with Trilantic North America and Halle Capital Management as continuing investors who have led additional financing rounds.
• The support-services model is the defining feature. Rarebreed markets itself as handling the back office — what it calls “uncommon support” — while letting on-site veterinary teams run the medicine, across a continuum-of-care network of general practice, PetMedic urgent care, and specialty and emergency hospitals.
• The footprint runs Maine to Florida along the Eastern Seaboard, with a strong Northeast concentration and roughly 130 locations across about 11 states per third-party tracking. If your practice sits inside or near that density, you fit Rarebreed’s geographic profile.
• The most reliable way to know what Rarebreed — or any major buyer — would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. Rarebreed is invited inside that rope on practices that fit their criteria — and when they bid against a curated group of qualified competitors, the number is reliably very different from what any single buyer would offer in a direct, one-on-one conversation.

When a vet hands me a Rarebreed offer and asks what to make of it, the conversation almost always starts with the same instinct from the owner: this one feels different from the big national platforms. That instinct isn’t wrong, and it’s worth understanding before you do anything with the paper in front of you. Selling your veterinary practice to Rarebreed Veterinary Partners means joining a younger, operator-led platform with a deliberately narrower geography and a model built around supporting the practice rather than absorbing it.

The way the company describes itself, the doctors keep running the medicine and Rarebreed takes the administrative weight off their shoulders.

That positioning is the through-line of every Rarebreed conversation. It shapes how the company recruits, how it talks to sellers, and where the real negotiation leverage sits once you get past the headline.

Both the headline and the fine print matter, but the locus of the decision is a little different here than with a twenty-year-old national consolidator.

What follows is the same picture I’d lay out over dinner if you handed me a Rarebreed term sheet. Who owns Rarebreed, how big it actually is, what the support-services model means for your day-to-day after closing, where the leverage in the negotiation really lives, and how to think about Rarebreed against the rest of the US veterinary buyer pool in a properly run process.

Who owns Rarebreed Veterinary Partners? (Revelstoke, Trilantic, Halle)

Rarebreed Veterinary Partners is majority-sponsored by Revelstoke Capital Partners, a Denver-based private equity firm, which made a significant recapitalization investment in December 2021. Earlier and continuing minority investors include Trilantic North America and Halle Capital Management.

Rarebreed remains operator-led, co-founded and run by CEO Dan Espinal.

The ownership story here is layered, and it matters for how you read the offer. Rarebreed was founded in 2018 and is headquartered in Portland, Maine per Revelstoke’s own portfolio page.

It was co-founded by Dan Espinal, who serves as CEO, and Sean Miller, who serves as COO. Espinal previously led IDEXX Laboratories’ in-house chemistry business and its corporate development and strategy team, so the platform was built by an operator with deep roots in the veterinary diagnostics world.

Trilantic North America came in as a minority investor earlier in Rarebreed’s life. At the time of that investment, Rarebreed operated roughly 17 clinics in the Northeastern US per Today’s Veterinary Business.

Halle Capital Management and Trilantic have since acted as continuing investors, leading additional financing rounds to fund Rarebreed’s hospital acquisitions per Private Equity Wire.

Then came the December 2021 recapitalization. Revelstoke’s portfolio page lists that investment date but does not state an exact ownership percentage, so the precise split between Revelstoke, Trilantic, and Halle isn’t public.

Lincoln International, which advised on the Revelstoke investment, characterized Rarebreed as a “highly differentiated, technology-enabled platform improving the veterinary experience for all stakeholders.” Trilantic’s own portfolio page still lists Rarebreed as an active investment, describing it as a Portland, Maine-based vertically integrated veterinary services platform across the Northeastern US.

One thing to set straight, because it circulates: there is no confirmed Berkshire connection to Rarebreed. The primary sources point squarely to Revelstoke as the majority sponsor since December 2021.

If you’ve seen a Berkshire reference attached to Rarebreed, treat it as stale.

Rarebreed at a glance: size, footprint, and the Maine-to-Florida network

Rarebreed operates approximately 130 veterinary locations across roughly 11 states, according to third-party tracker pets.care. The footprint stretches along the Eastern Seaboard from Maine to Florida, with the densest concentration in the Northeast and New England per Rarebreed’s own company site.

A fair-warning note on that count. The ~130-location, 11-state figure comes from a third-party tracker, not from Rarebreed itself.

The company’s homepage currently displays placeholder figures for its headline metrics, so the exact current number isn’t company-confirmed. The direction of travel, though, is well-documented through its acquisition history.

The clearest data point on Rarebreed’s growth is the Vet’s Best Friend deal. In July 2022, Rarebreed acquired Vet’s Best Friend, a Massachusetts-based group, adding 47 locations to its then-71-practice community and bringing the network to roughly 118 locations per dvm360.

That single transaction nearly doubled the platform and cemented its Northeast density.

The practical read for a seller: Rarebreed is a younger platform than the national consolidators, but it is no longer small, and it has shown it will do large, network-expanding deals. If your practice sits along the Eastern Seaboard — and especially in the Northeast — you are squarely inside the geography where Rarebreed builds regional clusters.

The Rarebreed model: support services and the continuum-of-care network

Rarebreed positions itself as a support-services partner — its term for an ownership model where the buyer handles back-office and administrative functions while the on-site veterinary team keeps running the medicine. The company markets this as “uncommon support,” and it’s the single feature that most distinguishes Rarebreed in how it presents itself to sellers.

Underneath that positioning sits a vertically integrated, tech-enabled network that spans the continuum of care — the full range of pet healthcare under one platform per Rarebreed’s company site. That continuum has three layers:

General practice. The core of the network — the kind of multi-doctor companion-animal practice that makes up most of Rarebreed’s footprint.

Urgent care via PetMedic. Rarebreed launched PetMedic as an urgent-care brand to handle after-hours, non-emergency cases. It has grown to roughly a dozen locations, concentrated in New England per the company site.

PetMedic is the layer that sits between a regular GP visit and a full emergency hospital.

Specialty and emergency hospitals. The top of the continuum, handling the cases that get referred up from general practice and urgent care.

On the team-support side, Rarebreed advertises resources including free CE courses, a yearly CE allowance, a mentorship program, and a dedicated field support team per its company site. The pitch to doctors and staff is built around development and support rather than rebranding and consolidation.

There’s also a partnership angle worth naming. Per a third-party profile citing one selling Maine practice’s stated rationale, Rarebreed takes a flexible, customizable partnership approach rather than a one-size-fits-all model, and offers equity to interested doctors and staff while emphasizing preservation of local control.

That framing comes from a seller’s stated reason for choosing Rarebreed, surfaced through a third-party profile rather than lifted from a Rarebreed seller page, so read it as directional rather than as a published guarantee. If equity and local control matter to you, those are exactly the items to pin down in writing.

What selling to Rarebreed looks like for a $2M+ GP owner

For a strong multi-doctor general practice in the $2 million-plus revenue range, Rarebreed is a credible bidder when the practice fits its Eastern Seaboard geography. What the deal actually looks like depends far more on whether other buyers are at the table than on anything Rarebreed publishes — because Rarebreed, like every buyer in this market, does not publish a standard price sheet.

Here’s the consistent pattern I see, and it isn’t specific to Rarebreed. When a multi-doctor practice receives a direct offer from any single buyer’s acquisition team, the offer reflects the leverage that buyer perceives in the conversation.

A single bidder facing no visible competition has no structural reason to lead with its strongest cash percentage, its tightest earnout protections — the part of the price paid later only if the practice hits agreed targets after closing — or its most flexible clinical-autonomy language. Inside a properly structured competitive process, where the buyer knows other qualified bidders are underwriting the same practice in parallel, those dimensions tend to move, sometimes meaningfully.

On where the dollars typically land: per industry M&A commentary across the PE-backed buyer pool (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in this revenue band tend to run in the low-teens EBITDA range — EBITDA being what your practice earns in pure operating profit, before taxes and accounting choices. That’s a market-wide directional read, not a Rarebreed-specific quote; Rarebreed’s specific offer on any specific deal is negotiated case by case under confidentiality.

Our PE pricing guide walks through how those ranges break down by practice profile, and our valuation guide covers how buyers build the EBITDA number in the first place.

On structure: per industry M&A commentary across the major buyer pool (Dechert LLP, Holland & Knight, Capstone Partners), the typical offer allocates the majority of total deal value to cash at close, with the remainder split among earnout, rollover equity — keeping a slice of ownership in the new entity instead of taking all cash — and occasional seller notes. Because Rarebreed has publicly leaned into offering equity to interested doctors, the rollover conversation is one you should expect to have, and one worth modeling carefully before you sign anything.

How Rarebreed positions itself vs. the big national consolidators

If you’re weighing a Rarebreed offer, you’re almost certainly comparing it implicitly to the larger national platforms. Here’s how Rarebreed’s positioning differs across the dimensions that matter.

Versus the national scale players. Rarebreed is younger and geographically tighter than the largest national consolidators. Where a national platform spans the entire country, Rarebreed builds density along one coast.

For a seller, that can mean a more regionally connected referral and support network if you’re inside the footprint — and a less natural fit if you’re outside it.

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic, family-owned exception in the US veterinary buyer pool per Mars company disclosures, which distinguishes it from Rarebreed’s PE-backed structure. Both can compete for qualifying practices in a structured sale process.

Our veterinary consolidators overview maps the full landscape of who’s buying.

Versus the other PE-backed platforms. Rarebreed’s calling card is the support-services framing and the continuum-of-care network with its own urgent-care brand in PetMedic. Other PE-backed groups emphasize different features — some lean harder into partnership and joint-venture structures, others into national scale or specialty depth.

The right way to find out which one actually pays and structures best for your specific practice is to put the relevant ones in the same competitive process and let them surface their best offers in parallel.

The honest summary: Rarebreed’s positioning is genuinely distinctive, and for the right practice in the right geography it’s an attractive home. But “distinctive positioning” and “best offer for your practice” are two different questions, and only a competitive process answers the second one.

Autonomy, equity, and partnership: what Rarebreed says it offers sellers

Three threads run through how Rarebreed talks to sellers: autonomy on the medicine, optional equity, and a partnership posture. Each is a genuine selling point, and each is also a place where the marketing language and the contract language need to match before you sign.

Clinical and operational autonomy. The whole support-services pitch rests on the idea that the doctors keep running the medicine. That’s a real and attractive promise, and it’s also exactly the kind of promise that belongs in the definitive purchase agreement rather than only in the recruiting deck.

Define which decisions stay with the on-site team and which migrate to the platform.

Equity for interested doctors and staff. Per the third-party profile noted earlier, Rarebreed offers equity to interested doctors and staff. If your offer includes rollover, the terms — liquidity windows, governance and information rights, anti-dilution protection — are where the value of that equity actually lives.

The specific multiple, the rollover percentage, and the earnout structure are not publicly disclosed by Rarebreed, so they have to be drawn out and compared, ideally against what other qualified buyers would put on the table.

Preservation of local control. The partnership framing emphasizes keeping local control intact. Again, that’s a strong fit for owners who want continuity for their team and clients — and again, “general approach” language is not the same as a contractual commitment.

Get the local-control and brand-handling specifics in writing.

The team-support resources — free CE, the yearly CE allowance, the mentorship program, the field support team — are real benefits that matter to your staff’s experience after closing. They’re a reason your team may be enthusiastic about the deal.

They are not, on their own, a substitute for negotiating the economic and autonomy terms that determine your outcome.

Is Rarebreed the right buyer for your practice? Key questions to ask

Rarebreed is among the active US veterinary acquirers in 2026 and a serious bidder for practices that fit its Eastern Seaboard footprint and support-services model. Whether it’s the right buyer for your practice comes down to a handful of specific questions you should answer before you commit.

Start with fit. Does your practice sit inside or near Rarebreed’s Maine-to-Florida density?

Does the continuum-of-care model — with internal urgent-care and specialty referral through PetMedic and the specialty hospitals — line up with how you practice? If yes on both, you’re a natural candidate.

Then move to the terms that actually determine your outcome. Here’s where I’d focus the negotiation:

Earnout protective provisions (highest priority). If the offer includes an earnout, negotiate no major operational changes without your consent during the earnout window, a working capital floor, an explicit prohibition on shifting central-services costs from other practices onto yours, and a clear definition of what counts in the EBITDA calculation at the earnout date.

Post-sale clinical autonomy. Put the support-services promise in the contract. Spell out that you make the medicine decisions, and define which business decisions stay with you versus moving to the platform.

Rollover equity terms. If equity is part of the offer, negotiate defined liquidity windows tied to specific milestones, governance and information rights, minority protection, and anti-dilution provisions. Model what the equity is plausibly worth, not just what it’s pitched as.

Cash at close. Push for the highest cash percentage the process supports. Every dollar moved from contingent to cash is guaranteed money instead of conditional money.

Non-compete scope. These commonly run several years over a defined radius. Negotiate shorter duration and a tighter radius, and carve out any modality you might continue working in.

Brand and local-control commitments. If local control and your practice’s identity matter to you, get the specifics — name, signage, website, marketing — written into the purchase agreement, even where they align with Rarebreed’s stated philosophy.

Have an offer from Rarebreed? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms, identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool. No upfront cost, no obligation.

How a competitive process changes a Rarebreed outcome

The mechanical reason a competitive process matters is the same for Rarebreed as for any buyer. Without competition, no buyer has a reason to soften the pre-set defaults in its standard template.

With competition, every term becomes negotiable, because every bidder knows the seller has real alternatives.

For Rarebreed specifically, the leverage tends to concentrate in two places: the structure and the autonomy language. Because Rarebreed has leaned publicly into equity and partnership framing, the rollover and partnership terms are exactly the kind of thing that sharpens when the seller has other qualified offers in hand.

And because the support-services model centralizes the back office, the clinical-autonomy and operational-decision carve-outs get more precise attention when other buyers are underwriting the same practice in the same window.

This is the heart of our Elite Selling System. We hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group.

From the 42-plus named veterinary consolidators we actively track, we invite only the ones that legitimately compete for your specific practice. For a practice in Rarebreed’s geography, that mix typically includes the regional and national platforms that would genuinely contend on footprint, structure, and autonomy — each one pushed to put its best full term sheet on the table, not just a headline number.

Bidders return complete term sheets, and you see them side by side: cash at close, earnout structure and protective provisions, rollover or partnership equity terms, non-compete scope, post-sale role, brand and local-control commitments. You choose on the dimensions that matter to you.

Sometimes that’s the platform with the most aligned model, sometimes the one with the most flexible autonomy, sometimes simply the highest total economic outcome.

When we prepare a practice for sale, part of the work is a thorough pre-sale financial review on our side of the table, built around exactly the kind of scrutiny the buyers’ accountants will run, but before any of those buyers see your numbers. That gives us months to clean up anything that wouldn’t survive a deep audit, so the EBITDA we present is the EBITDA that holds.

You can read more about the full path in our guide on how to sell a veterinary practice and how we think about matching owners to buyers in who to sell your veterinary practice to.

The result holds across deal types: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes — typically multiple seven figures, sometimes more — than the same practice would have cleared by signing the original direct term sheet without exploring the field. When the money changes hands at closing, the buyer wires the agreed funds directly to you and any lienholders in a simultaneous exchange, with any indemnification holdback being a portion the buyer retains and pays later rather than money sent off to a third party.

Closing thought

The honest read on Rarebreed Veterinary Partners: it’s a younger, operator-led, PE-backed platform with a genuinely distinctive support-services model and a tight Eastern Seaboard footprint that runs Maine to Florida. For the right practice in the right geography, it can be an excellent home — your team keeps running the medicine, the back office gets handled, and the continuum-of-care network gives your cases somewhere to go.

What separates a well-negotiated Rarebreed outcome from a mediocre one isn’t the marketing language about autonomy and partnership. It’s whether the contract actually delivers on that language, and whether you found out what the rest of the field would pay and offer before you committed.

The earnout protections, the rollover and equity terms, the clinical-autonomy carve-outs, the local-control commitments — those determine whether the model works in your favor.

If you’ve received a Rarebreed offer, or if their team has reached out to start the conversation, the highest-leverage move is to understand how the rest of the field would structure the same practice before you sign anything. Get a Free Practice Value Estimate and we’ll lay out the same offer-by-offer comparison we would for a client across a dinner table.

---

Frequently asked questions

Who owns Rarebreed Veterinary Partners?

Revelstoke Capital Partners, a Denver-based private equity firm, is the majority sponsor of Rarebreed Veterinary Partners following a significant recapitalization investment in December 2021. Trilantic North America and Halle Capital Management are continuing investors who have led additional financing rounds.

Rarebreed remains operator-led, co-founded and run by CEO Dan Espinal.

How many locations does Rarebreed Veterinary Partners have?

Rarebreed operates approximately 130 veterinary locations across roughly 11 states, according to third-party tracker pets.care. The footprint stretches along the Eastern Seaboard from Maine to Florida with a strong concentration in the Northeast.

The exact current count is not company-confirmed, since Rarebreed’s own homepage shows placeholder figures for its headline metrics.

Where is Rarebreed Veterinary Partners located?

Rarebreed Veterinary Partners is headquartered in Portland, Maine, and was founded in 2018. Its network of general practice, urgent care, and specialty and emergency hospitals runs along the Eastern Seaboard from Maine to Florida, with the densest concentration in the Northeast and New England.

Who is the CEO of Rarebreed Veterinary Partners?

Dan Espinal is the co-founder and CEO of Rarebreed Veterinary Partners. He co-founded the company in 2018 with Sean Miller (COO).

Before Rarebreed, Espinal led IDEXX Laboratories’ in-house chemistry business and its corporate development and strategy team. Rarebreed remains operator-led under his leadership.

What is the Rarebreed support-services and PetMedic model?

Rarebreed positions itself as a support-services partner that handles back-office and administrative functions while on-site veterinary teams run the medical side, marketed as “uncommon support.” It operates a continuum-of-care network spanning general practice, urgent care under its PetMedic brand for after-hours non-emergency cases, and specialty and emergency hospitals.

Does Rarebreed offer equity or rollover to selling veterinarians?

Per a third-party profile citing a selling practice’s stated rationale, Rarebreed takes a flexible, customizable partnership approach and offers equity to interested doctors and staff while emphasizing preservation of local control. The specific deal terms — including any rollover equity percentage, earnout structure, or multiple — are not publicly disclosed and are negotiated case by case under confidentiality.

Is Rarebreed Veterinary Partners a good company to sell my practice to?

Rarebreed is among the active US veterinary acquirers in 2026 and a serious bidder for practices that fit its Eastern Seaboard footprint and support-services model. Its continuum-of-care network and emphasis on letting on-site teams run the medicine are features sellers commonly evaluate.

As with any major buyer, Rarebreed is best evaluated head-to-head against a curated group of other qualified buyers in a competitive process.

What is the biggest negotiation point when selling to Rarebreed?

The earnout protective provisions and the post-sale clinical-autonomy language. Rarebreed’s support-services model centralizes back-office functions, so it is worth defining clearly which decisions stay with the on-site team and which migrate to the platform.

If the offer includes equity, the rollover terms and liquidity windows are the other high-leverage items to negotiate.

---

Sources

Rarebreed and investor materials

1. Revelstoke Capital Partners. Rarebreed Veterinary Partners portfolio page. revelstokecapital.com
2. Rarebreed Veterinary Partners. Company site — model, footprint, PetMedic, and team support. rarebreedvet.com
3. Rarebreed Veterinary Partners. Dan Espinal leadership profile. rarebreedvet.com
4. Trilantic North America. Rarebreed Veterinary Partners portfolio page. trilanticnorthamerica.com
5. Lincoln International. Rarebreed receives a significant investment from Revelstoke Capital Partners. lincolninternational.com

Acquisition history and financing

6. dvm360. Rarebreed Veterinary Partners announces acquisition of Vet’s Best Friend. dvm360.com
7. Today’s Veterinary Business. Rarebreed Partners, Trilantic investment. todaysveterinarybusiness.com
8. Private Equity Wire. Rarebreed Veterinary Partners closes new round of financing led by existing investors. privateequitywire.co.uk
9. CARE for Pets. Rarebreed Veterinary Partners profile — footprint and partnership approach. pets.care